Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
Biogen (NASDAQ: BIIB) stock rocketed to a six-year high earlier this week on news that its therapy, aducanumab, was the first Alzheimer's drug approved in nearly 20 years by the U.S. Food and Drug Administration (FDA). This is a huge deal, not only for Alzheimer's patients, but for Biogen and its shareholders. However, if you didn't get in on Biogen stock already, you'll pay dearly if you want to get in on the surge.
There are two other biotech stocks, however, whose recent breakthroughs could drive the profits for years to come, and they are still priced modestly -- for now.
Alkermes (NASDAQ: ALKS) just got approval this month from the FDA for Lybalvi (a combination of olanzapine and samidorphan) as a treatment for adults with schizophrenia and bipolar 1 disorder. Alpine Immune Sciences (NASDAQ: ALPN) is coming off a strong Phase 1 trial for ALPN-202, its immuno-oncology therapy to stimulate the body's immune systems to better fight several types of cancer, including pancreatic, colorectal, and uterine cancers.
Source Fool.com
